Navigation Links
Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease
Date:5/15/2009

> may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral and other infections due to opportunistic pathogens.

  • The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

    Serious and sometimes fatal infection due to bacterial, mycobacterial, invasive fungal, viral or other opportunistic pathogens has been reported in patients receiving TNF-blocking agents. Among opportunistic infections, tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis were the most common. Treatment with CIMZIA should not be initiated in patients with an active infection, including clinically important localized infections. The risks and benefits of treatment should be considered prior to initiating therapy in patients with chronic or recurrent infection, who have been exposed to tuberculosis, who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis, or with underlying conditions that may predispose them to infection.

    Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating CIMZIA and periodically during therapy. Patients should be closely monitored for the development of signs and symptoms of infections during and after treatment with CIMZIA, including developme
    '/>"/>

    SOURCE UCB
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine news :

    1. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
    2. UCBs CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
    3. Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohns Patients
    4. UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers
    5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
    6. New Online Project Management Fundamentals for Healthcare Module Available
    7. KT Tape: Secret Weapon of Elite Athletes - Now Available to Everyone
    8. Fiber Technology Products that Help Combat Spread of Superbugs Now Available to the Consumer Market
    9. Providence Service Corporation Makes Its Spring 2009 Presentation Publicly Available
    10. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
    11. Diatherix Laboratories Releases First Clinically Available Test For Confirmation of The Swine Flu Virus
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... 25, 2014 Reproductive Science Center (RSC) ... Dr. Kerri Luzzo, Lead Physician at RSC Rhode Island, ... professional accomplishments in fertility care and community outreach issued ... 10th Annual PBN Awards ceremony held July 24th at ... the most highly regarded, emerging leaders in their field ...
    (Date:7/25/2014)... The Little Gym of Houston will ... July 27 at Discovery Green in downtown Houston. The ... Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire ... “We’re thrilled to be attending and performing at the ... owns the Sugarland-Missouri City location. “We believe in the ...
    (Date:7/25/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Ibuprofen and Oxcarbazepine Tablets . , The ... and one lot of Oxcarbazepine Tablets, by American Health Packaging ... is used for the treatment of certain types of seizures ... the recall is that Lot #142588, Expiration Date, 01/2016 of ...
    (Date:7/25/2014)... (PRWEB) July 25, 2014 Ticket Down ... vs. Inter Milan tickets in Berkeley at California Memorial ... many new fans of football, the organizers of the 2014 ... best club teams to North America. With teams representing La ... tournament will bring some of the best football players from ...
    (Date:7/25/2014)... On July 22, 2014, ... and the nation’s number one provider of legally-compliant, ... their partnership with TransAct Merchant Solutions’ National Association ... of Chase Paymentech Solutions, LLC, which provides sales ... that are members of TransAct’s National Association Program ...
    Breaking Medicine News(10 mins):Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2
    ... March 3 The United States,Conference of Catholic ... February 27 approval of a new, bipartisan bill ... expected in March., Bishop Thomas G. Wenski ... International Justice and Peace, and Cardinal Justin Rigali ...
    ... Patient Access to ... ... Talecris Biotherapeutics, Inc. have donated $150,000 to Lucile,Packard Children,s Hospital at Stanford ... two,organizations announced today., PI is a term that encompasses more than ...
    ... a new tool designed to measure a womans willingness to ... transmission of HIV), researchers at The Miriam Hospital and Brown ... the past, and those with casual sexual partners were more ... , Although a safe and effective microbicide has not been ...
    ... Identifying Core Components of Spine Care Centers ... ... SpineMark Corporation,and NeuStrategy, Inc. have joined forces to conduct the ... provide an accounting of spine centers across the nation and uncover,spine ...
    ... release is available in German . ... of two phases: deep, dreamless slow-wave-sleep (SWS) alternates with ... studies suggest that information is processed and memories are ... in neurobiology. Comparative studies in birds may help to ...
    ... problems more likely in the overweight , , MONDAY, March ... likely than normal-weight children to have breathing-related problems during ... , The researchers, who looked at 1,380 normal-weight, 351 ... who had elective, non-cardiac surgery, found that obese children ...
    Cached Medicine News:Health News:Catholic Bishops Welcome New Bill for Global HIV/AIDS Relief 2Health News:Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford 2Health News:Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford 3Health News:Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford 4Health News:Researchers develop new tool to predict who will use microbicides 2Health News:Researchers develop new tool to predict who will use microbicides 3Health News:SpineMark, NeuStrategy Partner to Conduct Nation's First Spine COE Survey(TM) 2Health News:SpineMark, NeuStrategy Partner to Conduct Nation's First Spine COE Survey(TM) 3Health News:'Power napping' in pigeons 2Health News:Obese Children Face More Complications During Surgery 2
    (Date:7/24/2014)... July 24, 2014  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat ... fiscal 2015 first quarter ended June 30, 2014.  ...  PC Neuromodulation System grew 19% to $4.1 million, ... quarter of the prior year.  Total revenue for ...
    (Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
    (Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
    Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
    ... DIEGO, Jan. 10, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... Linda Amper, Ph.D., as Senior Vice President of Human ... Economics & Outcomes Research (HEOR), and John Womelsdorf, Ph.D., ... will strengthen the management team as the Company prepares ...
    ... Calif., Jan. 10, 2011 OncoMed Pharmaceuticals, Inc., ... today announced that patient dosing has commenced in a Phase ... tumor cancers.   OMP-59R5 is a monoclonal antibody ... to specifically block these targets to enter human studies.  The ...
    Cached Medicine Technology:Optimer Pharmaceuticals Announces Key Additions to Management Team 2Optimer Pharmaceuticals Announces Key Additions to Management Team 3Optimer Pharmaceuticals Announces Key Additions to Management Team 4OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 2OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 3
    Its generous filter placement, MicroPoint design, and reference marks at 10, 50, and 100 ul make this ART tip ideal for many 200 ul pipettors....
    With graduation marks at 10, 50, and 100 L and MicroPoint design, it is easy to ensure accurate sample handling on single and multichannel pipettors....
    Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
    10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
    Medicine Products: